ClinicalTrials.gg
Not yet recruitingNCT07950384VINCULO-ADIUpdated Nov 20, 2026

Vínculo: A Digital Intervention for Anxiety, Depression, and Insomnia Symptoms

An interventional study of Vínculo Digital Transdiagnostic Intervention and Digital Psychoeducation in Insomnia, Depressive Symptoms and Anxiety Symptoms, sponsored by University of Sao Paulo. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 45 studies in Sleep Initiation and Maintenance Disorders with a site in Brazil — 16 open to participants now, 17 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · Brazil.

Planned enrollment
8th of 41
305 · median 75
Started
2027
the only one that year
No phase
23 of 45
11 open now
Primary completion
2029-07
later than 15 of 16 live
Registered
45th of 45
by date
Lead sponsor
6 of 45
University of Sao Paulo

Among the 45 studies in Sleep Initiation and Maintenance Disorders with a site in Brazil, this one is the 8th largest by planned enrollment of the 41 interventional ones that give a count, is the only one that started in 2027, is one of 23 with no phase, reaches primary completion later than 15 of the 16 other live ones, and was the 45th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 734 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

16 of the 45 studies in Sleep Initiation and Maintenance Disorders with a site in Brazil are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 60 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Sleep Initiation and Maintenance Disorders with a site in Brazil, or all of them as a file.
02

Study summary

Insomnia, anxiety, and depression are common mental health problems that frequently occur together. Psychological interventions that address shared processes underlying these symptoms may offer an accessible way to improve mental health and sleep.

This study will evaluate the effectiveness of Vínculo, an eight-week, guided digital psychological intervention for adults experiencing clinically significant symptoms of insomnia, anxiety, and/or depression.

Approximately 305 adults living in Brazil will be randomly assigned to one of two groups. The experimental group will receive Vínculo, a psychological intervention delivered through a WhatsApp chatbot that combines acceptance and commitment therapy, behavioral activation, and behavioral strategies for sleep. The comparison group will receive an eight-week digital psychoeducation program covering mental health, emotions, sleep, and healthy lifestyle habits.

Both groups will receive structured content through WhatsApp, three individual videoconference sessions with a psychologist, and access to asynchronous psychological support during the intervention.

The main objective is to determine whether Vínculo is more effective than digital psychoeducation in reducing insomnia severity, depressive symptoms, and anxiety symptoms after eight weeks. Participants will also be assessed three and six months after the intervention to examine whether improvements are maintained. Additional assessments will examine daily functioning and psychological processes related to treatment outcomes.

Read the detailed description

This study is a fully remote, open-label, two-arm, parallel-group randomized controlled trial designed to evaluate the efficacy of Vínculo, a guided digital transdiagnostic psychological intervention, compared with an active digital psychoeducation control condition.

The study will enroll approximately 305 adults aged 18-59 years living in Brazil who report clinically significant symptoms in at least one of three domains: insomnia, depression, or anxiety. Eligibility will be established through electronic screening followed by a structured clinical assessment. A formal psychiatric diagnosis will not be required for inclusion.

After baseline assessment, participants will be randomized in a 1:1 ratio using computer-generated, randomly permuted blocks of varying sizes. Randomization will be stratified according to eight possible baseline symptom profiles, defined by the presence or absence of clinically significant insomnia, depression, and anxiety symptoms. Allocation will be implemented through REDCap.

The experimental intervention is based on process-based therapy and integrates components of acceptance and commitment therapy, behavioral activation, and behavioral strategies for insomnia. Therapeutic content will address emotional awareness, experiential avoidance, mindfulness, values clarification, committed action, behavioral activation, acceptance, cognitive defusion, sleep-related behaviors, and relapse prevention. Behavioral sleep strategies will be introduced in Week 4 and will not include sleep restriction.

The active control condition will provide structured psychoeducation about mental health, emotional symptoms, sleep, and healthy lifestyle habits without introducing the specific therapeutic techniques of the experimental intervention.

Both conditions will last eight weeks. Structured digital content will be delivered through WhatsApp three times weekly, with reminders on alternate days. Participants in both groups will receive three individual videoconference sessions with a psychologist and access to asynchronous professional support on business days. The content of professional support will be specific to each assigned condition.

The three co-primary outcomes are insomnia severity, depressive symptoms, and anxiety symptoms, assessed one week after completion of the eight-week intervention using the Insomnia Severity Index (ISI), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7), respectively.

Secondary assessments will examine symptom severity at three- and six-month follow-ups, functional impairment, clinical response, behavioral activation, and psychological flexibility. Exploratory assessments will address anhedonia and working alliance.

The primary analyses will compare treatment groups while accounting for baseline symptom severity. The study will also investigate treatment effects across different baseline symptom presentations and evaluate changes in psychological processes associated with clinical outcomes.

03

Conditions studied

  • Insomnia
  • Depressive Symptoms
  • Anxiety Symptoms

Keywords

  • Transdiagnostic Intervention
  • Digital Mental Health
  • Process-Based Therapy
  • Acceptance and Commitment Therapy
  • Behavioral Activation
  • Behavioral Sleep Intervention
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 59 years.
  • symptoms in at least one of the following domains at screening:
  • Insomnia: Insomnia Severity Index (ISI) score ≥11;
  • Depression: Patient Health Questionnaire-9 (PHQ-9) score ≥10;
  • Anxiety: Generalized Anxiety Disorder-7 (GAD-7) score ≥10.
  • Residence in Brazil.
  • Ability to read and understand written Portuguese.
  • Regular access to WhatsApp on a personal device.
  • Willingness and availability to participate in the intervention and complete the scheduled study assessments.
  • Provision of electronic .

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of bipolar disorder or psychotic disorder, or severe suicide risk.
  • Substance use disorder that would substantially interfere with participation in the intervention or completion of study assessments.
  • Severe and unstable neurological or medical conditions, such as dementia or advanced-stage cancer.
  • Night-shift work that cannot be reorganized.
  • Significant cognitive impairment that would hinder participation in the digital intervention.
  • Unavailability to participate in the intervention or complete the scheduled study assessments.
  • Use of sleep medication, either regularly or intermittently, without a stable medication use pattern for at least 2 months before enrollment, including recent initiation or substantial changes in the regimen.
  • Use of antidepressants or other psychotropic medications intended for regular use without a stable regimen for at least 1 month following a dose adjustment or 2 months following initiation of a new medication.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
305 participants (estimated)

Study arms

  • Experimental
    Vínculo Digital Intervention

    Participants will receive Vínculo, an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. The intervention integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep strategies. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days (Monday to Friday).

    Behavioral: Vínculo Digital Transdiagnostic Intervention

  • Active comparator
    Digital Psychoeducation

    Participants will receive an eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques used in the experimental intervention. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days (Monday to Friday), limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement.

    Behavioral: Digital Psychoeducation

Interventions

  • BehavioralVínculo Digital Transdiagnostic Intervention

    Vínculo is an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. Based on process-based therapy, it integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep regulation. Components include mindfulness, acceptance, cognitive defusion, values clarification, committed action, and behavioral activation. Sleep-related content is addressed throughout the intervention, including psychoeducation, stimulus control, a consistent wake time, daytime activity, morning natural light exposure, and a wind-down routine. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days.

  • BehavioralDigital Psychoeducation

    An eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides structured information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques of the experimental intervention. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days. Professional support is limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement.

06

What researchers measure

Primary outcomes

  1. Insomnia Symptom Severity (Insomnia Severity Index - ISI)

    The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. The primary outcome is the ISI total score at post-treatment, adjusted for baseline severity.

    Time frame: One week after completion of the 8-week intervention

  2. Depressive Symptom Severity (Patient Health Questionnaire-9 - PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. The primary outcome is the PHQ-9 total score at post-treatment, adjusted for baseline severity.

    Time frame: One week after completion of the 8-week intervention

  3. Anxiety Symptom Severity (Generalized Anxiety Disorder-7 - GAD-7)

    The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. The primary outcome is the GAD-7 total score at post-treatment, adjusted for baseline severity.

    Time frame: One week after completion of the 8-week intervention

Secondary outcomes

  1. Insomnia Symptom Severity at Follow-up (Insomnia Severity Index - ISI)

    The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. ISI total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity.

    Time frame: 3 and 6 months after completion of the 8-week intervention

  2. Depressive Symptom Severity at Follow-up (Patient Health Questionnaire-9 - PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. PHQ-9 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity.

    Time frame: 3 and 6 months after completion of the 8-week intervention

  3. Anxiety Symptom Severity at Follow-up (Generalized Anxiety Disorder-7 - GAD-7)

    The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. GAD-7 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity.

    Time frame: 3 and 6 months after completion of the 8-week intervention

  4. Functional Impairment (Sheehan Disability Scale - SDS)

    The Sheehan Disability Scale (SDS) is a three-item self-report measure assessing functional impairment in work or school, social life, and family life or home responsibilities. Each domain is scored from 0 to 10, with a total score ranging from 0 to 30. Higher scores indicate greater functional impairment.

    Time frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

  5. Behavioral Activation (Behavioral Activation for Depression Scale - Short Form, BADS-SF)

    The Behavioral Activation for Depression Scale - Short Form (BADS-SF) is a nine-item self-report measure assessing behavioral activation and avoidance. Total scores range from 0 to 54, with higher scores indicating greater behavioral activation. Changes in behavioral activation will be evaluated across the scheduled assessments.

    Time frame: Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

  6. Psychological Flexibility (Comprehensive Assessment of Acceptance and Commitment Therapy Processes - CompACT)

    The Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT) is a 23-item self-report measure assessing psychological flexibility through openness to experience, behavioral awareness, and valued action. Total scores range from 0 to 138, with higher scores indicating greater psychological flexibility.

    Time frame: Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

  7. Clinical Response in Insomnia Symptoms (ISI)

    Clinical response in insomnia symptoms will be defined as a reduction of at least 8 points in the Insomnia Severity Index (ISI) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment.

    Time frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

  8. Clinical Response in Depressive Symptoms (PHQ-9)

    Clinical response in depressive symptoms will be defined as a reduction of at least 50% in the Patient Health Questionnaire-9 (PHQ-9) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment.

    Time frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

  9. Clinical Response in Anxiety Symptoms (GAD-7)

    Clinical response in anxiety symptoms will be defined as a reduction of at least 50% in the Generalized Anxiety Disorder-7 (GAD-7) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment.

    Time frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

Other outcomes

  1. Anhedonia (Snaith-Hamilton Pleasure Scale - SHAPS)

    The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item self-report questionnaire assessing anhedonia, defined as a reduced capacity to experience pleasure. Using conventional dichotomous scoring, total scores range from 0 to 14, with higher scores indicating greater anhedonia. Changes in anhedonia will be evaluated as an exploratory outcome.

    Time frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

  2. Therapeutic Alliance (Working Alliance Inventory for Guided Internet Interventions - WAI-I)

    The Working Alliance Inventory for Guided Internet Interventions (WAI-I) is a self-report measure assessing the therapeutic alliance in guided internet-based psychological interventions, including agreement on therapeutic goals, agreement on tasks, and the therapeutic bond. Higher scores indicate a stronger therapeutic alliance. Therapeutic alliance will be evaluated as an exploratory outcome.

    Time frame: Week 4 and one week after completion of the 8-week intervention

07

Study locations

1 site
  • Institute of Psychology, University of São Paulo
    São Paulo, São Paulo 05508-030, Brazil
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data sharing has not yet been determined. Study data will be securely stored, and access will be restricted to authorized research personnel in accordance with institutional policies, ethical approvals, and Brazilian data protection legislation. The possibility of sharing de-identified participant data for scientific purposes will be evaluated in accordance with applicable ethical and institutional requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Jul 2029, 26 months later.

Of 1,218 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 26 months is above that.

Counting every sponsor, half of 1,296 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 20, 2026
StartEst.
May 2027
Primary completionEst.
Jul 2029
CompletionEst.
Nov 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950384
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo
Responsible party
Renatha El Rafihi-Ferreira (Associate Professor of Clinical Psychology, University of Sao Paulo) — Principal investigator
First posted
Nov 20, 2026
Start date
May 2027 (estimated)
Primary completion
Jul 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Renatha El Rafihi-Ferreira, PhD
Contact
protocolovinculo@gmail.com
+5511991841188
Renatha El Rafihi-Ferreira, PhD
principal investigator · University of Sao Paulo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion